Potential benefits of adaptive intensity-modulated proton therapy in nasopharyngeal carcinomas.
adaptive radiotherapy
dosimetric comparative study
intensity-modulated radiotherapy
nasopharyngeal carcinoma
proton beam therapy
Journal
Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
05
08
2020
revised:
24
11
2020
accepted:
25
11
2020
pubmed:
19
12
2020
medline:
22
6
2021
entrez:
18
12
2020
Statut:
ppublish
Résumé
To investigate potential advantages of adaptive intensity-modulated proton beam therapy (A-IMPT) by comparing it to adaptive intensity-modulated X-ray therapy (A-IMXT) for nasopharyngeal carcinomas (NPC). Ten patients with NPC treated with A-IMXT (step and shoot approach) and concomitant chemotherapy between 2014 and 2016 were selected. In the actual treatment, 46 Gy in 23 fractions (46Gy/23Fx.) was prescribed using the initial plan and 24Gy/12Fx was prescribed using an adapted plan thereafter. New treatment planning of A-IMPT was made for the same patients using equivalent dose fractionation schedule and dose constraints. The dose volume statistics based on deformable images and dose accumulation was used in the comparison of A-IMXT with A-IMPT. The means of the D An adaptive approach is suggested to enhance the potential benefit of IMPT compared to IMXT to reduce adverse effects for patients with NPC.
Identifiants
pubmed: 33338323
doi: 10.1002/acm2.13128
pmc: PMC7856494
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
174-183Subventions
Organisme : Ministry of Education
ID : 19K08088
Organisme : Ministry of Education
ID : 18H02758
Organisme : Japan Society for the Promotion of Science
Informations de copyright
© 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.
Références
Radiother Oncol. 2014 Jan;110(1):172-81
pubmed: 24183870
Med Dosim. 2014 Spring;39(1):34-7
pubmed: 24140235
Chin Clin Oncol. 2016 Apr;5(2):25
pubmed: 27121885
Sci Rep. 2015 Sep 01;5:13525
pubmed: 26323586
J Clin Oncol. 2017 Feb 10;35(5):498-505
pubmed: 27918720
Radiother Oncol. 2014 Jan;110(1):9-15
pubmed: 24332675
Acta Oncol. 2018 Oct;57(10):1284-1292
pubmed: 30289291
Radiat Oncol. 2015 Sep 17;10:192
pubmed: 26377685
Head Neck. 2016 Apr;38 Suppl 1:E2130-42
pubmed: 25546181
Radiat Oncol. 2019 Jan 21;14(1):14
pubmed: 30665451
Acta Oncol. 2015;54(8):1166-74
pubmed: 25850583
Radiother Oncol. 2014 Mar;110(3):390-7
pubmed: 24721546
Jpn J Clin Oncol. 2010 Feb;40(2):130-8
pubmed: 19841102
Int J Clin Oncol. 2020 Jul;25(7):1250-1259
pubmed: 32221802
Radiat Oncol. 2008 Jan 24;3:4
pubmed: 18218078
Head Neck. 2016 Apr;38 Suppl 1:E1886-95
pubmed: 26705956
J Radiat Res. 2014 Mar 1;55(2):293-304
pubmed: 23988444
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1256-62
pubmed: 18234431
Clin Transl Oncol. 2017 Apr;19(4):470-476
pubmed: 27718153
Oral Oncol. 2015 Nov;51(11):1041-1046
pubmed: 26296274
Radiat Oncol. 2013 Oct 14;8:237
pubmed: 24125432
Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):731-6
pubmed: 9112473
Eur Arch Otorhinolaryngol. 2020 Jul 4;:
pubmed: 32623508
Radiother Oncol. 2015 Oct;117(1):83-90
pubmed: 26277855
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):589-96
pubmed: 18793962
PLoS One. 2014 Apr 18;9(4):e94971
pubmed: 24747601
Phys Med Biol. 2016 Feb 21;61(4):1515-31
pubmed: 26815927
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):846-53
pubmed: 24867532
Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1360-8
pubmed: 20338474